PPARGC1A and Insulin resistance: -Decreased resting metabolic rate.-Enhanced mitochondrial efficiency and activity through AMPK-SIRT1-PGC-1α pathways.-Plasma glucose, triglycerides, and alanine aminotransferase (ALT) levels decreased significantly.-Systolic blood pressure is reduced by ~5 mmHg.-HOMA-IR (insulin resistance) improved by 25%.-Lowered inflammation markers (IL-6, TNF-α).